Cetera Investment Advisers’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.55M | Sell |
705,406
-15,958
| -2% | -$148K | 0.01% | 1033 |
|
|
2025
Q1 | $5.29M | Sell |
721,364
-2,476
| -0.3% | -$18.1K | 0.01% | 1073 |
|
|
2024
Q4 | $6.18M | Buy |
723,840
+4,342
| +0.6% | +$37.1K | 0.01% | 935 |
|
|
2024
Q3 | $6.26M | Sell |
719,498
-19,546
| -3% | -$170K | 0.01% | 899 |
|
|
2024
Q2 | $5.06M | Buy |
739,044
+13,054
| +2% | +$89.3K | 0.01% | 991 |
|
|
2024
Q1 | $6.61M | Buy |
725,990
+49,590
| +7% | +$451K | 0.02% | 838 |
|
|
2023
Q4 | $3.02M | Buy |
676,400
+66,300
| +11% | +$296K | 0.02% | 620 |
|
|
2023
Q3 | $1.92M | Sell |
610,100
-1,150
| -0.2% | -$3.61K | 0.02% | 771 |
|
|
2023
Q2 | $3.15M | Buy |
611,250
+10,100
| +2% | +$52.1K | 0.03% | 585 |
|
|
2023
Q1 | $3.17M | Buy |
601,150
+5,950
| +1% | +$31.4K | 0.03% | 547 |
|
|
2022
Q4 | $1.67M | Sell |
595,200
-9,350
| -2% | -$26.3K | 0.02% | 773 |
|
|
2022
Q3 | $2.51M | Buy |
604,550
+5,400
| +0.9% | +$22.4K | 0.05% | 388 |
|
|
2022
Q2 | $2.41M | Buy |
599,150
+32,400
| +6% | +$130K | 0.04% | 465 |
|
|
2022
Q1 | $2.81M | Buy |
566,750
+59,000
| +12% | +$292K | 0.04% | 449 |
|
|
2021
Q4 | $3.54M | Buy |
507,750
+75,650
| +18% | +$527K | 0.05% | 381 |
|
|
2021
Q3 | $4.32M | Buy |
+432,100
| New | +$4.32M | 0.07% | 293 |
|